CA2669123A1 - Inhibiteurs d'acat et leur utilisation dans la prevention ou le traitement de la fibrose - Google Patents

Inhibiteurs d'acat et leur utilisation dans la prevention ou le traitement de la fibrose Download PDF

Info

Publication number: CA2669123A1
Authority: CA; Canada
Prior art keywords: fibrosis; tissue; acat inhibitor; collagen; acat
Prior art date: 2006-11-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002669123A

Other languages

English (en)

Inventor

Siegfried Hekimi

Abdelmadjid K. Hihi

Robyn S. Branicky

Xihua Jia

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sosei Co Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-13

Filing date

2007-11-13

Publication date

2008-05-22

2007-11-13 Application filed by Individual filed Critical Individual

2008-05-22 Publication of CA2669123A1 publication Critical patent/CA2669123A1/fr

Status Abandoned legal-status Critical Current

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 102
230000004761 fibrosis Effects 0.000 title claims abstract description 59
206010016654 Fibrosis Diseases 0.000 title claims abstract description 53
230000002265 prevention Effects 0.000 title claims abstract description 12
238000011282 treatment Methods 0.000 title description 20
210000001519 tissue Anatomy 0.000 claims abstract description 65
NWLFOBZKYXKBOF-NSVAZKTRSA-N [(1s,2s)-2-[[2,2-dimethylpropyl(nonyl)carbamoyl]amino]cyclohexyl] 3-[[(4r)-2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl]amino]propanoate Chemical compound CCCCCCCCCN(CC(C)(C)C)C(=O)N[C@H]1CCCC[C@@H]1OC(=O)CCNC(=O)[C@H]1C(C)(C)COC(C)(C)O1 NWLFOBZKYXKBOF-NSVAZKTRSA-N 0.000 claims abstract description 62
239000000203 mixture Substances 0.000 claims abstract description 62
238000000034 method Methods 0.000 claims abstract description 49
102000008186 Collagen Human genes 0.000 claims abstract description 45
108010035532 Collagen Proteins 0.000 claims abstract description 45
229920001436 collagen Polymers 0.000 claims abstract description 45
PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 claims abstract description 23
230000008021 deposition Effects 0.000 claims abstract description 20
TXIIZHHIOHVWJD-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid Chemical compound CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 TXIIZHHIOHVWJD-UHFFFAOYSA-N 0.000 claims abstract description 17
229950003510 pactimibe Drugs 0.000 claims abstract description 16
JJNUVQIGQRFZAC-UHFFFAOYSA-N 8-(1,4,5-triphenylimidazol-2-yl)oxyoctanoic acid Chemical compound C=1C=CC=CC=1N1C(OCCCCCCCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JJNUVQIGQRFZAC-UHFFFAOYSA-N 0.000 claims abstract description 13
HGLFNRGXRCKGSW-UHFFFAOYSA-N 5-[(3,5-ditert-butyl-4-hydroxyanilino)-[[4-(2,2-dimethylpropyl)phenyl]methyl-hexylamino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1NC(=C1C(OC(C)(C)OC1=O)=O)N(CCCCCC)CC1=CC=C(CC(C)(C)C)C=C1 HGLFNRGXRCKGSW-UHFFFAOYSA-N 0.000 claims abstract description 12
210000002808 connective tissue Anatomy 0.000 claims abstract description 12
229950005522 octimibate Drugs 0.000 claims abstract description 12
AJLGIHBSQSODDV-UHFFFAOYSA-N 2-bromo-n-[2,6-di(propan-2-yl)phenyl]-6,11-dihydrobenzo[c][1]benzoxepine-11-carboxamide Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)C1C2=CC(Br)=CC=C2OCC2=CC=CC=C21 AJLGIHBSQSODDV-UHFFFAOYSA-N 0.000 claims abstract description 11
229950007075 eldacimibe Drugs 0.000 claims abstract description 11
WAFNZAURAWBNDZ-UHFFFAOYSA-N 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide Chemical compound CCCCCCCCCCC(C)(C)C(=O)NC1=C(OC)C=C(OC)C=C1OC WAFNZAURAWBNDZ-UHFFFAOYSA-N 0.000 claims abstract description 7
230000009467 reduction Effects 0.000 claims abstract description 6
230000015572 biosynthetic process Effects 0.000 claims description 37
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
210000004072 lung Anatomy 0.000 claims description 32
230000003176 fibrotic effect Effects 0.000 claims description 29
230000000694 effects Effects 0.000 claims description 23
210000000056 organ Anatomy 0.000 claims description 23
208000035475 disorder Diseases 0.000 claims description 22
229950010046 avasimibe Drugs 0.000 claims description 21
230000003510 anti-fibrotic effect Effects 0.000 claims description 19
210000003734 kidney Anatomy 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 12
210000004185 liver Anatomy 0.000 claims description 12
239000000546 pharmaceutical excipient Substances 0.000 claims description 12
208000005069 pulmonary fibrosis Diseases 0.000 claims description 12
ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
208000019425 cirrhosis of liver Diseases 0.000 claims description 10
238000011161 development Methods 0.000 claims description 10
229950005925 eflucimibe Drugs 0.000 claims description 10
230000002829 reductive effect Effects 0.000 claims description 10
210000000988 bone and bone Anatomy 0.000 claims description 9
210000004556 brain Anatomy 0.000 claims description 9
230000007423 decrease Effects 0.000 claims description 9
210000002216 heart Anatomy 0.000 claims description 9
210000000936 intestine Anatomy 0.000 claims description 9
210000000496 pancreas Anatomy 0.000 claims description 9
210000000952 spleen Anatomy 0.000 claims description 9
210000002784 stomach Anatomy 0.000 claims description 9
210000004291 uterus Anatomy 0.000 claims description 9
208000029523 Interstitial Lung disease Diseases 0.000 claims description 7
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
201000002793 renal fibrosis Diseases 0.000 claims description 6
231100000241 scar Toxicity 0.000 claims description 6
206010023421 Kidney fibrosis Diseases 0.000 claims description 5
208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 5
206010039710 Scleroderma Diseases 0.000 claims description 5
208000032544 Cicatrix Diseases 0.000 claims description 4
208000027932 Collagen disease Diseases 0.000 claims description 4
208000002260 Keloid Diseases 0.000 claims description 4
206010035664 Pneumonia Diseases 0.000 claims description 4
208000003782 Raynaud disease Diseases 0.000 claims description 4
208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
229940044683 chemotherapy drug Drugs 0.000 claims description 4
208000030533 eye disease Diseases 0.000 claims description 4
230000001969 hypertrophic effect Effects 0.000 claims description 4
210000001117 keloid Anatomy 0.000 claims description 4
208000017169 kidney disease Diseases 0.000 claims description 4
201000006370 kidney failure Diseases 0.000 claims description 4
201000000306 sarcoidosis Diseases 0.000 claims description 4
230000037387 scars Effects 0.000 claims description 4
230000029663 wound healing Effects 0.000 claims description 4
206010072877 Intestinal fibrosis Diseases 0.000 claims description 3
206010034665 Peritoneal fibrosis Diseases 0.000 claims description 3
230000009787 cardiac fibrosis Effects 0.000 claims description 3
201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
-1 TEI6522 Chemical compound 0.000 abstract description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
230000014509 gene expression Effects 0.000 description 25
241000699670 Mus sp. Species 0.000 description 21
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 21
150000001875 compounds Chemical class 0.000 description 21
108010006654 Bleomycin Proteins 0.000 description 19
241001465754 Metazoa Species 0.000 description 19
229960001561 bleomycin Drugs 0.000 description 19
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
239000003981 vehicle Substances 0.000 description 13
108020004999 messenger RNA Proteins 0.000 description 12
241000700159 Rattus Species 0.000 description 11
208000004608 Ureteral Obstruction Diseases 0.000 description 11
238000010171 animal model Methods 0.000 description 10
238000009472 formulation Methods 0.000 description 10
239000000463 material Substances 0.000 description 10
230000037361 pathway Effects 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
108010009583 Transforming Growth Factors Proteins 0.000 description 9
102000009618 Transforming Growth Factors Human genes 0.000 description 9
238000000540 analysis of variance Methods 0.000 description 9
230000003902 lesion Effects 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
101100008649 Caenorhabditis elegans daf-5 gene Proteins 0.000 description 8
102000001494 Sterol O-Acyltransferase Human genes 0.000 description 8
108010054082 Sterol O-acyltransferase Proteins 0.000 description 8
239000002775 capsule Substances 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
230000008569 process Effects 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
229960004308 acetylcysteine Drugs 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 6
229960000830 captopril Drugs 0.000 description 6
239000001768 carboxy methyl cellulose Substances 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
230000019491 signal transduction Effects 0.000 description 6
230000011664 signaling Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
101100008638 Caenorhabditis elegans daf-1 gene Proteins 0.000 description 5
101100386237 Caenorhabditis elegans daf-7 gene Proteins 0.000 description 5
101100386238 Caenorhabditis elegans daf-8 gene Proteins 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
235000012000 cholesterol Nutrition 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
208000037999 tubulointerstitial fibrosis Diseases 0.000 description 5
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
101100008636 Caenorhabditis elegans daf-14 gene Proteins 0.000 description 4
101100008648 Caenorhabditis elegans daf-4 gene Proteins 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
206010018364 Glomerulonephritis Diseases 0.000 description 4
102100030817 Liver carboxylesterase 1 Human genes 0.000 description 4
101710181187 Liver carboxylesterase 1 Proteins 0.000 description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
239000008112 carboxymethyl-cellulose Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000001508 eye Anatomy 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000013642 negative control Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000017423 tissue regeneration Effects 0.000 description 4
229940123324 Acyltransferase inhibitor Drugs 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241000282887 Suidae Species 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000002404 acyltransferase inhibitor Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
235000005911 diet Nutrition 0.000 description 3
230000037213 diet Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
108060002894 fibrillar collagen Proteins 0.000 description 3
102000013373 fibrillar collagen Human genes 0.000 description 3
230000000893 fibroproliferative effect Effects 0.000 description 3
239000000834 fixative Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 3
229960003073 pirfenidone Drugs 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
238000011002 quantification Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000008719 thickening Effects 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
SIHFCVXQGXGQQO-UHFFFAOYSA-N 1-cyclohexyl-1-[[4-[[cyclohexyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]cyclohexyl]methyl]-3-[4-(dimethylamino)phenyl]urea Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)N(C1CCCCC1)CC1CCC(CN(C2CCCCC2)C(=O)NC=2C=CC(=CC=2)N(C)C)CC1 SIHFCVXQGXGQQO-UHFFFAOYSA-N 0.000 description 2
NBYATBIMYLFITE-UHFFFAOYSA-N 3-[decyl(dimethyl)silyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide Chemical compound C=1C=CC=CC=1C(NC(=O)CC[Si](C)(C)CCCCCCCCCC)CC1=CC=C(C)C=C1 NBYATBIMYLFITE-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
101710085045 B2 bradykinin receptor Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000004852 Lung Injury Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
244000146510 Pereskia bleo Species 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
206010038923 Retinopathy Diseases 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
206010069363 Traumatic lung injury Diseases 0.000 description 2
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
210000001552 airway epithelial cell Anatomy 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000011553 hamster model Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002608 insulinlike Effects 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000001418 larval effect Effects 0.000 description 2
231100000516 lung damage Toxicity 0.000 description 2
231100000515 lung injury Toxicity 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
230000003562 morphometric effect Effects 0.000 description 2
238000013425 morphometry Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000008817 pulmonary damage Effects 0.000 description 2
230000002207 retinal effect Effects 0.000 description 2
230000037390 scarring Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000005556 structure-activity relationship Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000001069 triethyl citrate Substances 0.000 description 2
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
235000013769 triethyl citrate Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
LNDWMQWLWGXEET-UHFFFAOYSA-N 2-(1h-indol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2NC=CC2=C1 LNDWMQWLWGXEET-UHFFFAOYSA-N 0.000 description 1
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
MNTDTOWNMVZUMU-UHFFFAOYSA-N 8-amino-2,3-dihydrochromen-4-one Chemical class O=C1CCOC2=C1C=CC=C2N MNTDTOWNMVZUMU-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
241000244202 Caenorhabditis Species 0.000 description 1
241000244203 Caenorhabditis elegans Species 0.000 description 1
101100008646 Caenorhabditis elegans daf-3 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
208000029147 Collagen-vascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
102100027998 Macrophage metalloelastase Human genes 0.000 description 1
101710187853 Macrophage metalloelastase Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000001826 Marfan syndrome Diseases 0.000 description 1
102000011721 Matrix Metalloproteinase 12 Human genes 0.000 description 1
108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
102100022496 Mucin-5AC Human genes 0.000 description 1
108010063954 Mucins Proteins 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
108010035766 P-Selectin Proteins 0.000 description 1
102100023472 P-selectin Human genes 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
206010067953 Radiation fibrosis Diseases 0.000 description 1
206010063562 Radiation skin injury Diseases 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
241001357002 Scedosporium sp. Species 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
210000004712 air sac Anatomy 0.000 description 1
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
210000002821 alveolar epithelial cell Anatomy 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000009028 cell transition Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
230000001906 cholesterol absorption Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000011382 collagen catabolic process Effects 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000012136 culture method Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000007705 epithelial mesenchymal transition Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
230000009795 fibrotic process Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000002706 hydrostatic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000000871 hypocholesterolemic effect Effects 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
108700016226 indium-bleomycin Proteins 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000009114 investigational therapy Methods 0.000 description 1
ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000013227 male C57BL/6J mice Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
201000002674 obstructive nephropathy Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
108010016093 sterol O-acyltransferase 1 Proteins 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1
230000037314 wound repair Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002669123A 2006-11-13 2007-11-13 Inhibiteurs d'acat et leur utilisation dans la prevention ou le traitement de la fibrose Abandoned CA2669123A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US85834906P	2006-11-13	2006-11-13
US60/858,349		2006-11-13
US93575307P	2007-08-29	2007-08-29
US60/935,753		2007-08-29
PCT/CA2007/002032 WO2008058383A1 (fr)	2006-11-13	2007-11-13	Inhibiteurs d'acat et leur utilisation dans la prévention ou le traitement de la fibrose

Publications (1)

Publication Number	Publication Date
CA2669123A1 true CA2669123A1 (fr)	2008-05-22

Family

ID=39401277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002669123A Abandoned CA2669123A1 (fr)	2006-11-13	2007-11-13	Inhibiteurs d'acat et leur utilisation dans la prevention ou le traitement de la fibrose

Country Status (8)

Country	Link
EP (1)	EP1981493A4 (fr)
JP (1)	JP2010509247A (fr)
KR (1)	KR20100014267A (fr)
AU (1)	AU2007321667A1 (fr)
BR (1)	BRPI0718630A2 (fr)
CA (1)	CA2669123A1 (fr)
IL (1)	IL198721A0 (fr)
WO (1)	WO2008058383A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7625890B2 (en)	2005-11-10	2009-12-01	Smithkline Beecham Corp.	Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
WO2008138350A1 (fr) *	2007-05-14	2008-11-20	Sygehuset Glostrup	Prévention d'une fibrose intra-oculaire
US8614991B2 (en)	2008-04-25	2013-12-24	Kyocera Corporation	Wireless communication apparatus and communication apparatus
KR20130113921A (ko) *	2010-05-19	2013-10-16	코와 가부시키가이샤	비알코올성 지방성 간염의 예방 및/또는 치료제
US9164084B2 (en)	2012-01-31	2015-10-20	Purdue Research Foundation	Methods for determining aggressiveness of a cancer and treatment thereof
CN102670796A (zh) *	2012-05-22	2012-09-19	广西天天乐药业股份有限公司	一种治疗脾胃虚弱的中药及其制备方法
GB201917498D0 (en) *	2019-11-29	2020-01-15	Ucl Business Ltd	Treatment o f hepatitis b virus (hbv) infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2358400C (fr) *	1999-01-05	2012-05-15	Nancy A. Noble	Procedes de traitement d'etats associes a l'accumulation d'un excedent de matrice extracellulaire
RU2358734C2 (ru) *	2003-08-29	2009-06-20	Кова Ко., Лтд.	Способ стабилизации бляшки с высоким содержанием липидов и способ профилактики ее разрушения

2007
- 2007-11-13 EP EP07845502A patent/EP1981493A4/fr not_active Withdrawn
- 2007-11-13 WO PCT/CA2007/002032 patent/WO2008058383A1/fr not_active Ceased
- 2007-11-13 AU AU2007321667A patent/AU2007321667A1/en not_active Abandoned
- 2007-11-13 JP JP2009535540A patent/JP2010509247A/ja not_active Withdrawn
- 2007-11-13 CA CA002669123A patent/CA2669123A1/fr not_active Abandoned
- 2007-11-13 BR BRPI0718630-4A patent/BRPI0718630A2/pt not_active IP Right Cessation
- 2007-11-13 KR KR1020097012305A patent/KR20100014267A/ko not_active Withdrawn
2009
- 2009-05-12 IL IL198721A patent/IL198721A0/en unknown

Also Published As

Publication number	Publication date
AU2007321667A1 (en)	2008-05-22
EP1981493A4 (fr)	2009-11-11
WO2008058383A1 (fr)	2008-05-22
BRPI0718630A2 (pt)	2014-05-27
EP1981493A1 (fr)	2008-10-22
KR20100014267A (ko)	2010-02-10
JP2010509247A (ja)	2010-03-25
IL198721A0 (en)	2010-02-17

Publication	Publication Date	Title
KR100552043B1 (ko)	2006-02-20	푸마질롤 유도체를 포함하는 비만치료용 조성물
US9579315B2 (en)	2017-02-28	Methods of treating obstructive lung diseases using bitter tastants
CA2669123A1 (fr)	2008-05-22	Inhibiteurs d'acat et leur utilisation dans la prevention ou le traitement de la fibrose
Abidi et al.	2017	Nigella sativa, a traditional Tunisian herbal medicine, attenuates bleomycin-induced pulmonary fibrosis in a rat model
MX2011010631A (es)	2012-01-20	Metodos y composiciones de inhibidores de quinasa pi-3 para tratar fibrosis.
JPWO2021066144A1 (ja)	2021-12-02	ヘテロシクリデンアセトアミド誘導体含有医薬
AU2025205402A1 (en)	2025-07-31	New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
KR101340940B1 (ko)	2013-12-13	데커시놀 또는 데커시놀 엔젤레이트를 함유하는 퇴행성 신경질환의 예방 또는 치료용 조성물
CN103221043A (zh)	2013-07-24	用于治疗神经元连接发育障碍的erk抑制剂
US9505757B2 (en)	2016-11-29	Pharmaceutical composition comprising bicyclic pyridinol derivatives for preventing or treating diseases caused by angiogenesis
CN101129394B (zh)	2011-03-23	秦皮甲素预防和/或治疗心脑血管疾病的新用途
Zhang et al.	2025	The Tan-Re-Qing Capsule mitigates acute lung injury by suppressing the NLRP3 inflammasome and MAPK/NF-κB signaling pathways
US20220202801A1 (en)	2022-06-30	Use of compound in preparation of drug for treating atherosclerosis
KR102057441B1 (ko)	2019-12-19	벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
Zhang et al.	2025	Artemisinin-hydroxychloroquine combination from traditional antimalarial medicine attenuates pulmonary fibrosis via PI3K/AKT/GSK3β-mediated inhibition of epithelial-mesenchymal transition
US20250136661A1 (en)	2025-05-01	Pharmaceutical composition comprising adipose tissue-derived extracellular vesicle and biologic and use of pharmaceutical composition for treating arthritis
CN117720620B (zh)	2024-07-23	小分子多肽和其药物组合物、其制药用途
US6348488B1 (en)	2002-02-19	Remedies for motor dysfunction and GAPDH expression inhibitors
US8507506B2 (en)	2013-08-13	Theophylline derivative inhibits osteoporosis
Mo et al.	2025	Bisabolangelone targets Colony-stimulating factor 1 receptor (CSF1R) to impede osteoclastogenesis and attenuate estrogen-deficiency bone loss
CN101904843B (zh)	2014-04-30	化合物制备骨破坏抑制剂的用途
CN120131616A (zh)	2025-06-13	阿维a酸在制备治疗nlrp3炎症小体介导的疾病的药物中的应用、预防和/或治疗nlrp3炎症小体介导的疾病的药物组合物
HK40084623A (en)	2023-07-21	Use of glycerol phospholipids in the prevention and treatment of hyperlipidemia, atherosclerosis, non-alcoholic fatty liver and obesity
CN119424407A (zh)	2025-02-14	3,5,6,7,8,3’,4’-七甲氧基黄酮在制备预防或治疗肺纤维化的药物中的应用
KR20170094584A (ko)	2017-08-21	레바미피드 전구체를 포함하는 면역질환 및 대사성질환의 예방 또는 치료를 위한 경구투여용 약제학적 조성물

Legal Events

Date	Code	Title	Description
2011-11-14	FZDE	Discontinued